FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
13.94 USD
-0.16 (-1.15%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
34.03M
72.83M
46.83M
78.59M
47.07M
57.9M
71.22M
87.61M
107.76M
132.56M
Revenue %
-
114
-35.71
67.84
-40.11
23.01
23.01
23.01
23.01
Operating Cash Flow
88.13M
-128.95M
-153.09M
-102.83M
-194.5M
-34.74M
-42.73M
-52.57M
-64.66M
-79.53M
Operating Cash Flow %
258.95
-177.05
-326.92
-130.84
-413.2
-60
-60
-60
-60
Cap Ex
-9.1M
-1.6M
-2.84M
-34.48M
-12.84M
-12.29M
-15.12M
-18.59M
-22.87M
-28.13M
Cap Ex %
-26.73
-2.19
-6.06
-43.87
-27.27
-21.22
-21.22
-21.22
-21.22
Free Cash Flow
79.03M
-130.54M
-155.92M
-137.31M
-207.34M
-47.03M
-57.85M
-71.16M
-87.53M
-107.67M
Weighted Average Cost Of Capital
Price
34.49
Beta
Diluted Shares Outstanding
75.04M
Costof Debt
4.11
Tax Rate
After Tax Cost Of Debt
4.11
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
87.76M
Total Equity
2.59B
Total Capital
2.68B
Debt Weighting
3.28
Equity Weighting
96.72
Wacc
14.27
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
34.03M
72.83M
46.83M
78.59M
47.07M
57.9M
71.22M
87.61M
107.76M
132.56M
Operating Cash Flow
88.13M
-128.95M
-153.09M
-102.83M
-194.5M
-34.74M
-42.73M
-52.57M
-64.66M
-79.53M
Cap Ex
-9.1M
-1.6M
-2.84M
-34.48M
-12.84M
-12.29M
-15.12M
-18.59M
-22.87M
-28.13M
Free Cash Flow
79.03M
-130.54M
-155.92M
-137.31M
-207.34M
-47.03M
-57.85M
-71.16M
-87.53M
-107.67M
Wacc
14.27
14.27
14.27
14.27
14.27
Pv Lfcf
-41.16M
-44.3M
-47.68M
-51.33M
-55.25M
Sum Pv Lfcf
-239.72M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
14.27
Free Cash Flow T1
-109.82M
Terminal Value
-894.7M
Present Terminal Value
-459.12M
Intrinsic Value
Enterprise Value
-698.84M
Net Debt
-32.49M
Equity Value
-666.35M
Diluted Shares Outstanding
75.04M
Equity Value Per Share
-8.88
Projected DCF
-8.88 4.884%
